vTv Therapeutics (NASDAQ:VTVT) Share Price Passes Above 50 Day Moving Average - Time to Sell?

Key Points

• vTv Therapeutics' stock surpassed its 50-day moving average, reaching a trading high of $23.50, with a last traded price of $22.38.
• Analysts from HC Wainwright maintain a "buy" rating for vTv Therapeutics, setting a price target of $36.00, while the consensus target is $35.50.
• The company recently reported a loss of ($0.92) earnings per share, missing the consensus estimate by $0.07.

vTv Therapeutics Inc. (NASDAQ:VTVT - Get Free Report)'s share price passed above its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $16.73 and traded as high as $23.50. vTv Therapeutics shares last traded at $22.38, with a volume of 25,633 shares.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a "buy" rating and issued a $36.00 target price on shares of vTv Therapeutics in a report on Wednesday, August 13th. Two research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $35.50.

vTv Therapeutics Price Performance

The company has a market capitalization of $71.17 million, a P/E ratio of -7.15 and a beta of 0.64. The business has a 50-day moving average of $16.84 and a 200-day moving average of $17.46.

vTv Therapeutics (NASDAQ:VTVT - Get Free Report) last issued its quarterly earnings results on Tuesday, August 12th. The biotechnology company reported ($0.92) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.85) by ($0.07).

Institutional Trading of vTv Therapeutics

An institutional investor recently bought a new position in vTv Therapeutics stock. Connective Capital Management LLC purchased a new position in vTv Therapeutics Inc. (NASDAQ:VTVT - Free Report) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 9,377 shares of the biotechnology company's stock, valued at approximately $162,000. Connective Capital Management LLC owned about 0.29% of vTv Therapeutics as of its most recent SEC filing. 17.51% of the stock is owned by hedge funds and other institutional investors.

vTv Therapeutics Company Profile

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.